惠泰医疗
(688617)
| 流通市值：336.77亿 | | | 总市值：336.77亿 |
| 流通股本：6686.14万 | | | 总股本：6686.14万 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 654,177,314.01 | 1,276,391,305.21 | 451,530,046.17 | 717,224,525.44 |
| 应收票据及应收账款 | 42,638,141.24 | 41,777,915.87 | 50,493,490.69 | 35,796,438.56 |
| 其中：应收票据 | 219,391.6 | 362,131.9 | - | - |
| 应收账款 | 42,418,749.64 | 41,415,783.97 | 50,493,490.69 | 35,796,438.56 |
| 预付款项 | 37,690,749.98 | 38,134,839.35 | 40,876,995.28 | 35,496,166.1 |
| 其他应收款合计 | 4,688,473.5 | 4,459,882.1 | 4,420,092.81 | 5,297,893.73 |
| 其中:应收利息 | 416,645.13 | - | - | - |
| 存货 | 349,660,493.93 | 327,953,140.74 | 352,168,883.43 | 350,332,067.04 |
| 其他流动资产 | 2,167,880.48 | 7,349,900.98 | 1,938,784.17 | 2,291,169.54 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,666,720,650.96 | 1,756,066,984.25 | 1,673,178,348.37 | 1,585,396,915.1 |
| 非流动资产: | | | | |
| 长期股权投资 | 40,947,765.72 | 38,655,456.4 | 33,271,269.47 | 34,132,501.77 |
| 其他权益工具投资 | 121,147,733.44 | 121,147,733.44 | 129,118,055.18 | 129,118,055.18 |
| 固定资产 | 418,154,509.3 | 399,366,483.38 | 357,037,764.61 | 334,754,388.72 |
| 在建工程 | 63,270,803.5 | 47,844,356.76 | 32,254,051.09 | 22,943,076.29 |
| 使用权资产 | 14,773,624.88 | 17,253,111.91 | 17,839,297.15 | 16,777,143.73 |
| 无形资产 | 81,439,767.7 | 83,004,883.09 | 61,581,594.84 | 62,907,158.83 |
| 商誉 | 48,133,117.11 | 48,133,117.11 | 51,981,262.9 | 51,981,262.9 |
| 长期待摊费用 | 5,230,904.77 | 5,951,799.1 | 5,858,356.84 | 6,528,768.96 |
| 递延所得税资产 | 9,564,389.08 | 10,732,163.28 | 12,845,392.21 | 15,523,948.79 |
| 其他非流动资产 | 138,701,262.65 | 44,826,206.72 | 69,130,030.61 | 62,605,416.76 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 941,363,878.15 | 816,915,311.19 | 770,917,074.9 | 737,271,721.93 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,608,084,529.11 | 2,572,982,295.44 | 2,444,095,423.27 | 2,322,668,637.03 |
| 流动负债: | | | | |
| 短期借款 | - | 70,000,000 | 70,000,000 | 103,000,000 |
| 应付票据及应付账款 | 68,119,457.9 | 42,726,085.19 | 54,436,280.92 | 43,646,791.58 |
| 应付账款 | 68,119,457.9 | 42,726,085.19 | 54,436,280.92 | 43,646,791.58 |
| 合同负债 | 43,896,909.86 | 44,395,898.73 | 31,687,103.6 | 49,400,131.4 |
| 应付职工薪酬 | 60,250,759.34 | 124,700,480.37 | 111,312,866.02 | 75,480,491.86 |
| 应交税费 | 26,296,230.45 | 24,362,333.17 | 25,556,898.17 | 29,943,523.7 |
| 其他应付款合计 | 274,398,089.59 | 265,863,882.66 | 262,980,687.84 | 267,410,025.73 |
| 一年内到期的非流动负债 | 10,510,819.33 | 11,279,474.09 | 16,438,512.68 | 15,372,334.55 |
| 其他流动负债 | 2,965,740.83 | 4,841,674.71 | 2,080,824.73 | 4,135,637.94 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 486,438,007.3 | 588,169,828.92 | 574,493,173.96 | 588,388,936.76 |
| 非流动负债: | | | | |
| 长期借款 | 295,500 | 591,000 | 886,500 | 1,182,000 |
| 租赁负债 | 6,254,861.38 | 7,988,002.78 | 9,414,389.29 | 9,333,465.36 |
| 递延收益 | 8,284,213.99 | 8,744,929.6 | 8,765,946.66 | 9,109,245.43 |
| 递延所得税负债 | 3,622,562.61 | 5,487,670.79 | 13,012,219.27 | 13,069,038.44 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 18,457,137.98 | 22,811,603.17 | 32,079,055.22 | 32,693,749.23 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 504,895,145.28 | 610,981,432.09 | 606,572,229.18 | 621,082,685.99 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 66,861,357 | 66,861,357 | 66,851,051 | 66,851,051 |
| 资本公积 | 727,386,458.09 | 724,040,835.54 | 718,406,353.58 | 714,352,666.84 |
| 减:库存股 | 59,990,496.75 | 59,990,496.75 | 59,990,496.75 | 59,990,496.75 |
| 其他综合收益 | 34,924,707.84 | 34,962,596.62 | 41,405,579.21 | 41,475,142.57 |
| 盈余公积 | 33,430,678.5 | 33,430,678.5 | 30,753,510.54 | 30,753,510.54 |
| 未分配利润 | 1,247,981,165.52 | 1,107,837,337.76 | 979,837,626.1 | 833,985,718.56 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,050,593,870.2 | 1,907,142,308.67 | 1,777,263,623.68 | 1,627,427,592.76 |
| 少数股东权益 | 52,595,513.63 | 54,858,554.68 | 60,259,570.41 | 74,158,358.28 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,103,189,383.83 | 1,962,000,863.35 | 1,837,523,194.09 | 1,701,585,951.04 |
| 负债和股东权益合计 | 2,608,084,529.11 | 2,572,982,295.44 | 2,444,095,423.27 | 2,322,668,637.03 |
| 公告日期 | 2024-04-26 | 2024-03-25 | 2023-10-27 | 2023-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |